文献速递冠心病

网状血小板在冠心病中的促血栓信号与治疗新靶点

Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究从95例冠心病患者中分离网状血小板与成熟血小板进行配对比较,整合转录组学、高维蛋白质组学和功能实验,揭示网状血小板富集促血栓通路、GPVI剪接变体及非编码RNA,并证实PI3K与GPVI抑制可显著减少其聚集、铺展和血栓形成。

要点

  • 网状血小板高表达活化标志物并富集促血栓通路。
  • GPVI和PI3K信号通路在网状血小板中活性增强。
  • 抑制PI3K或GPVI可显著减少网状血小板介导的血栓形成。

核心结论

  • 网状血小板在冠心病中具有独特的分子与功能表型,其高反应性由GPVI和PI3K信号通路介导,抑制这些通路可减少血栓形成。

研究设计与样本

  • 从95例冠心病患者中基于RNA含量和CD41表达分离网状血小板与成熟血小板,在每个供者内进行配对比较。
  • 整合转录组测序、高维蛋白质组学(质谱流式)并在独立队列中验证,同时进行功能实验评估PI3K和GPVI通路的影响。

主要发现

  • 与成熟血小板相比,网状血小板活化标志物表达升高且促血栓通路富集。
  • RNA-seq显示GP6、TBXA2R和VWF转录本上调,存在新的GPVI剪接变体及网状血小板特异性非编码RNA(包括新型circRNA)。
  • 蛋白质组和功能实验证实PI3K和GPVI信号增强,AKT、PI3K和SYK磷酸化增加,活性氧产生增多。
  • 网状血小板聚集、铺展和血栓形成中的募集增加,可被PI3K抑制剂LY294002和GPVI抑制剂glenzocimab显著减少。

临床怎么用

  • 对于网状血小板升高的冠心病患者,GPVI和PI3K抑制可能成为定制抗血小板治疗的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Reticulated platelets (RPs), hyperreactive and RNA-rich, are associated with increased risk of cardiovascular events and suboptimal response to antiplatelet therapy in coronary artery disease (CAD). However, the underlying mechanisms remain poorly defined. This study aimed to characterize the molecular and functional phenotype of RPs in CAD and assess their potential as therapeutic targets. METHODS: RPs and mature platelets (MPs) were isolated from CAD patients based on RNA content and CD41 expression. Paired RP vs MP comparisons were conducted within each donor. Transcriptomic profiling (RNA-seq) was integrated with high-dimensional proteomics (mass cytometry) and validated in independent cohorts. Functional studies, including flow cytometry-based platelet-platelet binding, in vitro thrombosis, platelet spreading, and intracellular phospho-protein profiling, assessed the impact of PI3K and GPVI pathways. Results were curated in Platlas, an open-access interactive web resource. RESULTS: Among 95 CAD patients, RPs exhibited elevated activation marker expression and enrichment of prothrombotic pathways compared with MPs. RNA-seq revealed upregulation of GP6, TBXA2R, and VWF transcripts, novel GPVI splicing, and RP-specific non-coding RNAs including novel circRNAs. Proteomic and functional assays confirmed heightened PI3K and GPVI signalling, with increased phosphorylation of AKT, PI3K, and SYK, and elevated reactive oxygen species production. RPs showed increased aggregation, spreading and greater recruitment in thrombus formation, which were significantly reduced by PI3K (LY294002) and GPVI (glenzocimab) inhibition. CONCLUSIONS: This study provides the first mechanistic explanation for RP hyperreactivity, revealing a distinct molecular profile and identifying GPVI and PI3K inhibition as promising targets for tailored antiplatelet therapy in CAD patients with elevated RPs.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kirmes K, Han J, Klug M, et al. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Eur Heart J. 2025. PMID: 40886063. doi:10.1093/eurheartj/ehaf694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。